PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of archdischfnArchives of Disease in Childhood - Fetal & NeonatalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Arch Dis Child Fetal Neonatal Ed. 2005 July; 90(4): F286–F289.
PMCID: PMC1721903

Palivizumab for preterm infants. Is it worth it?

Full Text

The Full Text of this article is available as a PDF (70K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr. 1993 Feb;23(2):50–79. [PubMed]
  • Simoes EA. Respiratory syncytial virus infection. Lancet. 1999 Sep 4;354(9181):847–852. [PubMed]
  • Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003 Dec;88(12):1065–1069. [PMC free article] [PubMed]
  • Handforth Jenny, Sharland Mike, Friedland Jon S. Prevention of respiratory syncytial virus infection in infants. BMJ. 2004 May 1;328(7447):1026–1027. [PMC free article] [PubMed]
  • Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996 Aug 3;313(7052):275–283. [PMC free article] [PubMed]
  • Feltes Timothy F, Cabalka Allison K, Meissner H Cody, Piazza Franco M, Carlin David A, Top Franklin H, Jr, Connor Edward M, Sondheimer Henry M. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532–540. [PubMed]
  • Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000 Nov;19(11):1068–1071. [PubMed]
  • Oh Paul I, Lanctôt Krista L, Yoon Alice, Lee David S C, Paes Bosco A, Simmons Brian S, Parison Diana, Manzi Patricia. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002 Jun;21(6):512–518. [PubMed]
  • Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Jr, Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998 Feb;17(2):110–115. [PubMed]
  • Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH, Jr, Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998 Sep;17(9):787–791. [PubMed]
  • Lacaze-Masmonteil Thierry, Seidenberg Juergen, Mitchell Ian, Cossey Veerle, Cihar Martin, Csader Michal, Baarsma Rienk, Valido Marques, Pollack Paul F, Groothuis Jessie R, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf. 2003;26(4):283–291. [PubMed]
  • Groothuis JR. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. Pediatr Infect Dis J. 2001 Jun;20(6):628–630. [PubMed]
  • Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000 May;161(5):1501–1507. [PubMed]
  • Legg Julian P, Hussain Imran R, Warner Jill A, Johnston Sebastian L, Warner John O. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003 Sep 15;168(6):633–639. [PubMed]
  • Strutton David R, Stang Paul E. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making. J Pediatr. 2003 Nov;143(5 Suppl):S157–S162. [PubMed]
  • Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000 Oct;83(4):313–316. [PMC free article] [PubMed]
  • McCormick Jonathan, Tubman Richard. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol. 2002 Oct;34(4):262–266. [PubMed]
  • Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child. 2000 Aug;83(2):122–127. [PMC free article] [PubMed]
  • Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott Med J. 2003 Nov;48(4):108–110. [PubMed]
  • Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, Chetcuti PA, Shaw NJ, Woods A, Boorman J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001 Dec;85(6):463–468. [PMC free article] [PubMed]
  • Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics. 1999 Sep;104(3 Pt 1):559–560. [PubMed]
  • Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999 Sep;104(3 Pt 1):419–427. [PubMed]
  • Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health. 2002 Aug;38(4):352–357. [PubMed]
  • Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000 Jan;154(1):55–61. [PubMed]
  • Roeckl-Wiedmann Irmgard, Liese Johannes G, Grill Eva, Fischer Birgit, Carr David, Belohradsky Bernd H. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003 Apr;162(4):237–244. [PubMed]
  • Kamal-Bahl Sachin, Doshi Jalpa, Campbell James. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034–1041. [PubMed]
  • Sampalis John S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003 Nov;143(5 Suppl):S150–S156. [PubMed]
  • Lenney W. Palivizumab and RSV prevention. Arch Dis Child. 2000 Jul;83(1):87–87. [PubMed]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Group